254 related articles for article (PubMed ID: 36016371)
41. Characterization of hepatitis B and delta coinfection in Israel.
Shirazi R; Ram D; Rakovsky A; Bucris E; Gozlan Y; Lustig Y; Shaked-Mishan P; Picard O; Shemer-Avni Y; Ben-Zvi H; Halutz O; Lurie Y; Veizman E; Carlebach M; Braun M; Naftaly MC; Shlomai A; Safadi R; Mendelson E; Sklan EH; Ben-Ari Z; Mor O
BMC Infect Dis; 2018 Feb; 18(1):97. PubMed ID: 29486716
[TBL] [Abstract][Full Text] [Related]
42. HDV evolution-will viral resistance be an issue in HDV infection?
Tabernero D; Cortese MF; Buti M; Rodriguez-Frias F
Curr Opin Virol; 2018 Oct; 32():100-107. PubMed ID: 30415162
[TBL] [Abstract][Full Text] [Related]
43. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt.
Saudy N; Sugauchi F; Tanaka Y; Suzuki S; Aal AA; Zaid MA; Agha S; Mizokami M
J Med Virol; 2003 Aug; 70(4):529-36. PubMed ID: 12794714
[TBL] [Abstract][Full Text] [Related]
44. Liver Transplantation in Hepatitis B/Hepatitis D (Delta) Virus Coinfected Recipients.
Martini S; Tandoi F; Romagnoli R; Rizzetto M
Transplantation; 2022 Oct; 106(10):1935-1939. PubMed ID: 35404869
[TBL] [Abstract][Full Text] [Related]
45. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.
Hønge BL; Jespersen S; Medina C; Té Dda S; da Silva ZJ; Lewin S; Østergaard L; Erikstrup C; Wejse C; Laursen AL; Krarup H;
PLoS One; 2014; 9(6):e99971. PubMed ID: 24915064
[TBL] [Abstract][Full Text] [Related]
46. Emerging anti-HDV drugs and HBV cure strategies with anti-HDV activity.
Roca Suarez AA; Batbold E; Bartosch B; Dashdorj N; Testoni B; Zoulim F
Liver Int; 2023 Aug; 43 Suppl 1():87-95. PubMed ID: 37017060
[TBL] [Abstract][Full Text] [Related]
47. True prevalence of twin HDV-HBV infection in Pakistan: a molecular approach.
Khan AU; Waqar M; Akram M; Zaib M; Wasim M; Ahmad S; Niaz Z; Ali S; Ali H; Idrees M; Bajwa MA
Virol J; 2011 Sep; 8():420. PubMed ID: 21888671
[TBL] [Abstract][Full Text] [Related]
48. Hepatitis D virus: an update.
Pascarella S; Negro F
Liver Int; 2011 Jan; 31(1):7-21. PubMed ID: 20880077
[TBL] [Abstract][Full Text] [Related]
49. Hepatitis D virus: Improving virological knowledge to develop new treatments.
Khalfi P; Kennedy PT; Majzoub K; Asselah T
Antiviral Res; 2023 Jan; 209():105461. PubMed ID: 36396025
[TBL] [Abstract][Full Text] [Related]
50. Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan.
Lu MY; Chen CT; Shih YL; Tsai PC; Hsieh MH; Huang CF; Yeh ML; Huang CI; Wang SC; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Dai CY; Chuang WL; Yu ML; Chang WY
Sci Rep; 2021 Apr; 11(1):8554. PubMed ID: 33879825
[TBL] [Abstract][Full Text] [Related]
51. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome.
Heidrich B; Serrano BC; Idilman R; Kabaçam G; Bremer B; Raupach R; Önder FO; Deterding K; Zacher BJ; Taranta A; Bozkaya H; Zachou K; Tillmann HL; Bozdayi AM; Manns MP; Yurdaydın C; Wedemeyer H
Liver Int; 2012 Oct; 32(9):1415-25. PubMed ID: 22716112
[TBL] [Abstract][Full Text] [Related]
52. A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN-β induction.
Suárez-Amarán L; Usai C; Di Scala M; Godoy C; Ni Y; Hommel M; Palomo L; Segura V; Olagüe C; Vales A; Ruiz-Ripa A; Buti M; Salido E; Prieto J; Urban S; Rodríguez-Frias F; Aldabe R; González-Aseguinolaza G
J Hepatol; 2017 Oct; 67(4):669-679. PubMed ID: 28527664
[TBL] [Abstract][Full Text] [Related]
53. Characterization of the transcripts of hepatitis D and B viruses in infected human livers.
Chen PJ; Yang PM; Chen CR; Chen DS
J Infect Dis; 1989 Dec; 160(6):944-7. PubMed ID: 2584763
[TBL] [Abstract][Full Text] [Related]
54. Influence of hepatitis delta virus superinfection on the clearance of hepatitis B virus (HBV) markers in HBV carriers in Japan.
Ichimura H; Tamura I; Tsubakio T; Kurimura O; Kurimura T
J Med Virol; 1988 Sep; 26(1):49-55. PubMed ID: 3183634
[TBL] [Abstract][Full Text] [Related]
55. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
Samuel D; Zignego AL; Reynes M; Feray C; Arulnaden JL; David MF; Gigou M; Bismuth A; Mathieu D; Gentilini P
Hepatology; 1995 Feb; 21(2):333-9. PubMed ID: 7843702
[TBL] [Abstract][Full Text] [Related]
56. Epidemiology, presentation, and therapeutic approaches for hepatitis D infections.
Blaney H; Khalid M; Heller T; Koh C
Expert Rev Anti Infect Ther; 2023 Feb; 21(2):127-142. PubMed ID: 36519386
[TBL] [Abstract][Full Text] [Related]
57. Dynamics of in vivo hepatitis D virus infection.
Goyal A; Murray JM
J Theor Biol; 2016 Jun; 398():9-19. PubMed ID: 27012516
[TBL] [Abstract][Full Text] [Related]
58. What is the Path Forward to Treat Hepatitis Delta Virus?: Old Treatments and New Options.
Asselah T
Clin Liver Dis; 2023 Nov; 27(4):985-995. PubMed ID: 37778781
[TBL] [Abstract][Full Text] [Related]
59. Hepatitis delta in HIV/HBV co-infected patients in Brazil: is it important?
Mendes-Correa MC; Gomes-Gouvêa MS; Alvarado-Mora MV; Da Silva MH; Lázari C; Cavalcanti NC; Alonso FK; Carpinelli CC; Uip DE; Pinho JR
Int J Infect Dis; 2011 Dec; 15(12):e828-32. PubMed ID: 21999909
[TBL] [Abstract][Full Text] [Related]
60. Assessment of hepatitis B virus DNA levels in chronic HBsAg carriers with or without hepatitis delta virus superinfection.
Bas C; Bartolomé J; La Banda F; Porres JC; Quiroga JA; Mora I; Carreño V
J Hepatol; 1988 Apr; 6(2):208-13. PubMed ID: 3411100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
